Galectin-9 blockade synergizes with ATM inhibition to induce potent anti-tumor immunity

Although current cancer immunotherapies that target PD-1/PD-L1 immune checkpoint to reinvigorate exhausted T cells have achieved impressive clinical outcomes, only a small proportion of patients respond. New therapeutic targets are therefore needed to be identified to further unleash the anti-tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Shuang, Song, Jiaming, Linghu, Dongli, Yang, Riyao, Liu, Boning, Xue, Zhen, Chen, Qihui, Liu, Chengjie, Zhong, Diansheng, Hung, Mien-Chie, Sun, Linlin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2023
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909994/
https://www.ncbi.nlm.nih.gov/pubmed/36778120
http://dx.doi.org/10.7150/ijbs.79852

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909994/
https://www.ncbi.nlm.nih.gov/pubmed/36778120
http://dx.doi.org/10.7150/ijbs.79852

Ejemplares similares